橋本研究室

橋本研究室の業績リスト

  1. Hashimoto M, Ho G, Takamatsu Y, Wada R, Sugama S, Waragai M, Masliah E, Takenouchi T. Understanding Creutzfeldt-Jackob disease from a viewpoint of amyloidogenic evolvability. Prion. 2020 Dec;14(1):1-8. doi: 10.1080/19336896.2020.1761514.
  2. Waragai M, Ho G, Takamatsu Y, Wada R, Sugama S, Takenouchi T, Masliah E, Hashimoto M. Adiponectin Paradox as a Therapeutic Target in Alzheimer's Disease. J Alzheimers Dis. 2020 Jul 2. doi: 10.3233/JAD-200416.
  3. Takamatsu Y, Ho G, Hashimoto M. Amyloid Evolvability and Cancer. Trends Cancer. 2020 Aug;6(8):624-627. doi: 10.1016/j.trecan.2020.04.001. Epub 2020 May 5.
  4. Fujita M, Ho G, Takamatsu Y, Wada R, Ikeda K, Hashimoto M. Possible Role of Amyloidogenic Evolvability in Dementia with Lewy Bodies: Insights from Transgenic Mice Expressing P123H β-Synuclein. Int J Mol Sci. 2020 Apr 19;21(8):2849. doi: 10.3390/ijms21082849.
  5. Waragai M, Ho G, Takamatsu Y, Wada R, Sugama S, Takenouchi T, Masliah E, Hashimoto M. Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability? Front Endocrinol (Lausanne). 2020 Mar 4;11:108. doi: 10.3389/fendo.2020.00108. eCollection 2020.
  6. Sugama S, Takenouchi T, Hashimoto M, Ohata H, Takenaka Y, Kakinuma Y. J Stress-induced microglial activation occurs through β-adrenergic receptor: noradrenaline as a key neurotransmitter in microglial activation. Neuroinflammation. 2019 Dec 17;16(1):266. doi: 10.1186/s12974-019-1632-z.
  7. Ho G, Takamatsu Y, Waragai M, Wada R, Sugama S, Takenouchi T, Fujita M, Ali A, Hsieh MH, Hashimoto M. Current and future clinical utilities of Parkinson's disease and dementia biomarkers: can they help us conquer the disease? Expert Rev Neurother. 2019 Nov;19(11):1149-1161. doi:10.1080/14737175.2019.1649141. Epub 2019 Aug 9.
  8. Hashimoto M, Ho G, Takamatsu Y, Wada R, Sugama S, Takenouchi T, Waragai M, Masliah E. Possible Role of Amyloid Cross-Seeding in Evolvability and Neurodegenerative Disease. J Parkinsons Dis. 2019;9(4):793-802. doi: 10.3233/JPD-191675.
  9. Takamatsu Y, Ho G, Waragai M, Wada R, Sugama S, Takenouchi T, Masliah E, Hashimoto M. Transgenerational Interaction of Alzheimer's Disease with Schizophrenia through Amyloid Evolvability. J Alzheimers Dis. 2019;68(2):473-481. doi: 10.3233/JAD-180986.
  10. Takamatsu Y, Fujita M, Ho G, Wada R, Sugama S, Takenouchi T, Waragai M, Masliah M, and Hashimoto M. Motor- and non-motor symptoms of Parkinson’s disease; antagonistic pleiotropy phenomena derived from α-synuclein evolvability? Parkinson’s Dis. 2018 Nov 22;2018:5789424. doi: 10.1155/2018/5789424.
  11. Hashimoto M, Ho G, Takamatsu Y, Wada R, Sugama S, Takenouchi T, Masliah E, Waragai M. Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability. J Huntington’s Dis. 2018;7(4):297-307. doi: 10.3233/JHD-180309.
  12. Hashimoto M, Ho G, Takamatsu Y, Shimizu Y, Sugama S, Takenouchi T, Waragai M, Masliah E. Evolvability and Neurodegenerative Disease: Antagonistic Pleiotropy Phenomena Derived from Amyloid Aggregates. J Parkinson’s Dis. 2018;8(3):405-408. doi: 10.3233/JPD-181365.
  13. Waragai M, Ho G, Takamatsu Y, Shimizu Y, Sugino H, Sugama S, Takenouchi T, Masliah E, Hashimoto M. Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases. Drug Discov. Today 2018 Jun;23(6):1305-1311. doi: 10.1016/j.drudis.2018.05.009. Epub 2018 May 7.
  14. Fujita M, Hagino Y, Takamatsu Y, Shimizu Y, Takamatsu Y, Ikeda K, Hashimoto M, Early manifestation of depressive-like behavior in transgenic mice that express dementia with Lewy body-linked mutant β-synuclein Neuropsychopharmacology Reports 2018 Jun;38(2):95-97. doi: 10.1002/npr2.12009. Epub 2018 Mar 7.
  15. Hashimoto M, Ho G, Sugama S, Takamatsu Y, Shimizu Y, Takenouchi T, Waragai M, Masliah E. Evolvability of Amyloidogenic Proteins in Human Brain. J Alzheimers Dis. 2018;62(1):73-83. doi: 10.3233/JAD-170894.
  16. Hashimoto M, Ho G, Shimizu Y, Sugama S, Takenouchi T, Waragai M, Wei J, Takamatsu Y. Potential Application of Centrifuges to Protect the CNS in Space and on Earth. Curr Alzheimer Res. 2018;15(6):544-551. doi: 10.2174/1567205015666171229225501.
  17. Waragai M, Ho G, Takamatsu Y, Sekiyama K, Sugama S, Takenouchi T, Masliah E, Hashimoto M. Importance of adiponectin activity in the pathogenesis of Alzheimer's disease. Ann Clin Transl Neurol. 2017 Jul 11;4(8):591-600.
  18. Takamatsu Y, Ho G, Koike W, Sugama S, Takenouchi T, Waragai M, Wei J, Sekiyama K, Hashimoto M. Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases. npj Parkinson’s Disease 2017, 3 Article number 4
  19. Takamatsu Y, Koike W, Takenouchi T, Sugama S, Wei J, Waragai M, Sekiyama K, Hashimoto M. Protection against neurodegenerative disease on Earth and in space. npj Microgravity 2016, 2 Article number: 16013
  20. Waragai M, Adame A, Trinh I, Sekiyama K, Takamatsu Y, Une K, Masliah E, Hashimoto M. Possible Involvement of Adiponectin, the Anti-Diabetes Molecule, in the Pathogenesis of Alzheimer's Disease. J Alzheimers Dis. 2016, 52:1453-9.
  21. Sekiyama K, Takamatsu Y, Koike W, Waragai M, Takenouchi T, Sugama S, Hashimoto M. Insight into the Dissociation of Behavior from Histology in Synucleinopathies and in Related Neurodegenerative Diseases. J Alzheimers Dis. 2016, 52:831-41.
  22. Sugama S, Sekiyama K, Kodama T, Takamatsu Y, Takenouchi T, Hashimoto M, Bruno C, Kakinuma Y. Chronic restraint stress triggers dopaminergic and noradrenergic neurodegeneration: Possible role of chronic stress in the onset of Parkinson's disease. Brain Behav Immun. 2016, 51:39-46.
  23. Takenouchi T, Tsukimoto M, Iwamaru Y, Sugama S, Sekiyama K, Sato M, Kojima S, Hashimoto M, Kitani H. Extracellular ATP induces unconventional release of glyceraldehyde-3-phosphate dehydrogenase from microglial cells. Immunol Lett. 2015, 167:116-24.
  24. Sekigawa A, Takamatsu Y, Sekiyama K, Hashimoto M. Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies. Biomolecules. 2015, 5:1000-11.
  25. Sekiyama K, Waragai M, Akatsu H, Sugama S, Takenouchi T, Takamatsu Y, Fujita M, Sekigawa A, Rockenstein E, Inoue S, La Spada AR, Masliah E, Hashimoto M. Disease-Modifying Effect of Adiponectin in Model of α-Synucleinopathies. Ann Clin Transl Neurol. 2014, 1: 479-89.
  26. Sekiyama K, Takamatsu Y, Waragai M, Hashimoto M.Role of genomics in translational research for Parkinson's disease. Biochem Biophys Res Commun. 2014, 452: 226-35.
  27. Takenouchi T, Tsukimoto M, Hashimoto M, Kitani H. Inflammasome activation by danger signals: extracellular ATP and pH. Inflammasome 2014, 1: 2300-2.
  28. Sekigawa A, Sekiyama K, Fujita M, Takamatsu Y, La Spada AR, Masliah E, Hashimoto M. Dual effects of β-synuclein on the pathogenesis of Parkinson disease. Ann Neurol. 2013, 74:306.
  29. Sekigawa A, Takamatsu Y, Sekiyama K, Takenouchi T, Sugama S, Waragai M, Fujita M, Hashimoto M. Diversity of mitochondrial pathology in a mouse model of axonal degeneration in synucleinopathies. Oxid Med Cell Longev. 2013, 817807.
  30. Sugama S, Takenouchi T, Fujita M, Kitani H, Conti B, Hashimoto M. Corticosteroids limit microglial activation occurring during acute stress. Neuroscience. 2013, 232:13-20.
  31. Waragai M, Sekiyama K, Fujita M, Tokuda T, Hashimoto M. Biomarkers for the diagnosis and management of Parkinson's disease. Expert Opin Med Diagn. 2013, 7:71-83.
  32. Desplats P, Patel P, Kosberg K, Mante M, Patrick C, Rockenstein E, Fujita M, Hashimoto M, Masliah E. Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease. Mol Neurodegener. 2012, 7: 49.
  33. Fujita M, Sekigawa A, Sekiyama K, Takamatsu Y, Hashimoto M. Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathies. Int J Mol Sci. 2012, 13:11584-92.
  34. Fujita M, Hashimoto M. Perspective on the Role of beta-synuclein in the pathogenesis of alpha-synucleinopathies. Neuropathology New Research (Estevo Almeirão and Thiago Honrado, Ed), Nova Science Publishers: New York 2012. 4th Quarter ISBN: 978-1-62257-584-8
  35. Sekigawa A, Fujita M, Sekiyama K, Takamatsu Y, Hatano T, Rockenstein E, La Spada AR, Masliah E, Hashimoto M. Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H β-synuclein. Mol Brain. 2012, 5:34.
  36. Takenouchi T, Iwamaru Y, Imamura M, Fukuhara S, Sugama S, Sato M, Mochizuki N, Hashimoto M, Yokoyama T, Mohri S, Kitani H. Cytochalasin D enhances the accumulation of a protease-resistant form of prion protein in ScN2a cells: involvement of PI3 kinase/Akt signalling pathway. Cell Biol Int. 2012, 36:1223-31.
  37. Sekiyama K, Sugama S, Fujita M, Sekigawa A, Takamatsu Y, Waragai M, Takenouchi T, Hashimoto M. Neuroinflammation in Parkinson's Disease and Related Disorders: A Lesson from Genetically Manipulated Mouse Models of α-Synucleinopathies. Parkinsons Dis. 2012, 271732.
  38. Hashimoto M, La Spada AR. β-Synuclein in the pathogenesis of Parkinson’s disease and relatedα-synucleinopathies: Emerging roles and new directions. Future Neurol. 2012, 7: 155-63
  39. Waragai M, Yoshida M, Mizoi M, Saiki R, Kashiwagi K, Takagi K, Arai H, Tashiro J, Hashimoto M, Iwai N, Uemura K, Igarashi K. Increased Protein-Conjugated Acrolein and Amyloid-β40/42 Ratio in Plasma of Patients with Mild Cognitive Impairment and Alzheimer's Disease. J Alzheimers Dis. 2012, 32:33-41.
  40. Sekiyama K, Nakai M, Fujita M, Takenouchi T, Waragai M, Wei J, Sugama S, Sekigawa A, Takamatsu Y, Kitani H, Hashimoto M. Theaflavins stimulate autophagic degradation of α-synuclein in neuronal cells. Open J of Neurosci. 2012, 2-1
  41. Sekiyama K, Fujita M, Sekigawa A, Takamatsu Y, Waragai M, Takenouchi T, Sugama S, Hashimoto M. Ibuprofen ameliorates protein aggregation and astrocytic gliosis, but not cognitive dysfunction, in a transgenic mouse expressing dementia with Lewy bodies-linked P123H β-synuclein. Neurosci Lett. 2012, 515: 97-101.
  42. Takenouchi T, Iwamaru Y, Sugama S, Tsukimoto M, Fujita M, Sekigawa A, Sekiyama K, Sato M, Kojima S, Conti B, Hashimoto M, Kitani H. The activation of P2X7 receptor induces cathepsin D-dependent production of a 20-kDa form of IL-1β under acidic extracellular pH in LPS-primed microglial cells. J Neurochem. 2011, 117: 712-23.
  43. Ho GJ, Liang W, Waragai M, Sekiyama K, Masliah E, Hashimoto M. Bridging molecular genetics and biomarkers in lewy body and related disorders. Int J Alzheimers Dis. 2011, 842475.
  44. Sugama S, Takenouchi T, Sekiyama K, Kitani H, Hashimoto M. Immunological responses of astroglia in the rat brain under acute stress: interleukin 1 beta co-localized in astroglia. Neuroscience. 2011, 192: 429-37.
  45. Waragai M, Sekiyama K, Sekigawa A, Takamatsu Y, Fujita M, Hashimoto M. α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease. Int J Mol Sci. 2010, 11: 4257-66.
  46. Fujita M, Sugama S, Sekiyama K, Sekigawa A, Tsukui T, Nakai M, Waragai M, Takenouchi T, Takamatsu Y, Wei J, Rockenstein E, LaSpada AR, Masliah E, Inoue S, Hashimoto M. Αβ-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat. Commun. 2010 Nov2, 10.1038/ncomms1101
  47. Takenouchi, T.; Sekiyama, K.; Sekigawa, A.; Fujita, M.; Waragai, M.; Sugama, S.; Iwamaru, Y.; Kitani, H.; Hashimoto, M. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz) 2010, 58, (2), 91-6.
  48. Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M. Neurotoxic conversion of b-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies? J Neurol. 2009;256 Suppl 3:286-92.
  49. Sugama S, Takenouchi T, Cho BP, Joh TH, Hashimoto M, Kitani H. Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. Inflamm Allergy Drug Targets 2009 Sep;8(4):277-84.
  50. Takenouchi T, Sugama S, Iwamaru Y, Hashimoto M, Kitani H. Modulation of the ATP-lnduced Release and Processing of IL-1beta in Microglial Cells. Crit Rev Immunol. 2009;29(4):335-45.
  51. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P. Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem Cell Biol. 2009, 41(10), 2015-24.
  52. Crews L, Tsigelny I, Hashimoto M, Masliah E. Role of Synucleins in Alzheimer's Disease. Neurotox Res. 2009, 16(3), 306- 317.
  53. Wei J, Fujita M, Sekigawa A, Sekiyama K, Waragai M, Hashimoto M. Gangliosides proteaction against lysosomal pathology in a cellular model of Synucleinopathies. Autophagy. 2009, 5(6), 860- 861.
  54. Takenouchi T, Fujita M, Sugama S, Kitani H, Hashimoto M. The role of P2X7 Receptor signaling pathway for the release of autophagolysosomes in microglial cells. Autophagy. 2009, 5(5), 723- 724.
  55. Wei J, Fujita M, Nakai M, Waragai M, Sekigawa A, Sugama S, Takenouchi T, Masliah E, Hashimoto M. Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies Am. J Pathol. 2009, 174(5), 1891-1909.
  56. Sugama, S Takenouchi T, Kitani H, Fujita, M, Hashimoto M, Microglial activation is inhibited by corticosterone in dopaminergic neurodegeneration J Neuroimmunol. 2009, 208(1-2), 104-114.
  57. Takenouchi T, Nakai M, Iwamaru Y, Sugama S, Tsukimoto, M, Fujita M, Wei J, Sekigawa A, Sato M, Kojima, S, Kitani H, Hashimoto M. The Activation of P2X7 Receptor Impairs Lysosomal Functions and Stimulates the Release of Autophagolysosomes in Microglial Cells. J Immunol. 2009, 182(4), 2051-2062.
  58. Sugama, S Takenouchi T, Fujita M, Conti B, Hashimoto M, Differential microglial activation between acute stress and lipopolysaccharide treatment J Neuroimmunol. 2009, 207(1-2), 24-31.
  59. Kawahara K, Hashimoto M, Bar~on P, Ho GJ, Crews L, Mizuno H, Rockenstien E, Imam SZ, Masliah E. alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson’s disease. J Biol. Chem. 2008, 283(11), 6979-6987.
  60. Takenouchi T, Iwamaru Y, Sugama S, Sato M, Hashimoto M, Kitani H. Lysophospholipids and ATP mutually suppress maturation and release of IL-1 beta in mouse microglial cells using a Rho-dependent pathway. J Immunol. 2008, 180(12), 7827-7839.
  61. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci. 2008, 65, 1272-84.
  62. Wei J, Fujita M, Nakai M, Waragai M, Watabe K, Akatsu H, Rockenstein E, Masliah E, Hashimoto M. Enhanced lysosomal pathology caused by beta -synuclein mutants linked to dementia with lewy bodies. J Biol. Chem. 2007, 282(39):28904-14
  63. Fujita M, Sugama S, Nakai M, Takenouchi T, Wei J, Urano T, Inoue S, Hashimoto M. alpha-Synuclein stimulates differentiation of osteosarcoma cells: relevance to down-regulation of proteasome activity. J Biol. Chem. 2007, 282(8):5736-48.
  64. Sugama S, Takenouchi T, Kitani H, Fujita M, Hashimoto M. Activin as an anti-inflammatory cytokine produced by microglia. J Neuroimmunol. 2007, 192, 31-9.
  65. Waragai M, Nakai M, Wei J, Fujita M, Mizuno H, Ho G, Masliah E, Akatsu H, Yokochi F, Hashimoto M. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett. 2007, 425, 18-22.
  66. Takenouchi T, Iwamaru Y, Imamura M, Kato N, Sugama S, Fujita M, Hashimoto M, Sato M, Okada H, Yokoyama T, Mohri S, Kitani H. Prion infection correlates with hypersensitivity of P2X7 nucleotide receptor in a mouse microglial cell line. FEBS Lett. 2007, 581, 3019-26.
  67. Nakai M, Fujita M, Waragai M, Sugama S, Wei J, Akatsu H, Ohtaka-Maruyama C, Okado H, Hashimoto M. Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage. Biochem Biophys Res Commun. 2007, 358, 104-10.
  68. Sugama S, Fujita M, Hashimoto M, Conti B. Stress induced morphological microglial activation in the rodent brain: involvement of interleukin-18. Neuroscience. 2007, 146, 1388-99.
  69. Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J. 2007, 274, 1862-77.

ページトップへもどる